CA2939655A1 - Modulateurs de caspase 6 - Google Patents

Modulateurs de caspase 6 Download PDF

Info

Publication number
CA2939655A1
CA2939655A1 CA2939655A CA2939655A CA2939655A1 CA 2939655 A1 CA2939655 A1 CA 2939655A1 CA 2939655 A CA2939655 A CA 2939655A CA 2939655 A CA2939655 A CA 2939655A CA 2939655 A1 CA2939655 A1 CA 2939655A1
Authority
CA
Canada
Prior art keywords
treatment
caspase
neurological disease
pharmaceutical composition
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2939655A
Other languages
English (en)
Inventor
Medhi Mike Khankischpur
Olga PETINA
Detlef Geffken
Dagmar ERNHOEFER
Michael Hayden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Universitaet Hamburg
Original Assignee
University of British Columbia
Universitaet Hamburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, Universitaet Hamburg filed Critical University of British Columbia
Publication of CA2939655A1 publication Critical patent/CA2939655A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/28—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having nitrogen atoms of imino groups acylated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2939655A 2014-02-14 2015-02-14 Modulateurs de caspase 6 Abandoned CA2939655A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61/939,922 2014-02-14
US201462033401P 2014-08-05 2014-08-05
US62/033,401 2014-08-05
PCT/IB2015/000144 WO2016020732A1 (fr) 2014-08-05 2015-02-14 Modulateurs de caspase 6

Publications (1)

Publication Number Publication Date
CA2939655A1 true CA2939655A1 (fr) 2016-02-11

Family

ID=55263221

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2939655A Abandoned CA2939655A1 (fr) 2014-02-14 2015-02-14 Modulateurs de caspase 6

Country Status (6)

Country Link
EP (1) EP3129027A4 (fr)
JP (1) JP2018522812A (fr)
AU (1) AU2015298491A1 (fr)
CA (1) CA2939655A1 (fr)
DE (1) DE112015001269T5 (fr)
WO (1) WO2016020732A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016144702A1 (fr) 2015-03-06 2016-09-15 Pharmakea, Inc. Inhibiteurs de la lysyl oxydase-like 2 et utilisations desdits inhibiteurs
SG11201707246YA (en) 2015-03-06 2017-10-30 Pharmakea Inc Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
EP3414229B1 (fr) 2016-02-09 2021-06-16 Pharmakea, Inc. Inhibiteurs quinolinone de la lysyl oxydase-like 2 et utilisations desdits inhibiteurs
KR102587178B1 (ko) 2016-09-07 2023-10-06 파마케아, 인크. 리실 옥시다아제-유사 2 억제제의 결정질 형태 및 제조 방법
EP3509594A4 (fr) 2016-09-07 2020-05-06 Pharmakea, Inc. Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase
US20230202974A1 (en) * 2019-11-22 2023-06-29 The Regents Of The University Of California Caspase 6 inhibitors and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69700616T2 (de) * 1996-07-02 2000-03-16 Nisshin Flour Milling Co Imid derivate
WO2008076805A2 (fr) * 2006-12-15 2008-06-26 Bristol-Myers Squibb Company Analogues d'arylpropionamide, d'arylacrylamide, d'arylpropynamide ou d'arylméthylurée en tant qu'inhibiteurs du facteur xia
WO2010017408A1 (fr) * 2008-08-06 2010-02-11 The Buck Institute For Age Research Inhibiteurs de caspase, et leurs utilisations

Also Published As

Publication number Publication date
WO2016020732A1 (fr) 2016-02-11
EP3129027A4 (fr) 2017-06-21
DE112015001269T5 (de) 2017-06-08
JP2018522812A (ja) 2018-08-16
AU2015298491A1 (en) 2016-09-01
EP3129027A1 (fr) 2017-02-15

Similar Documents

Publication Publication Date Title
CA2939655A1 (fr) Modulateurs de caspase 6
RU2410376C2 (ru) Противовоспалительные агенты
WO2009047728A2 (fr) Nouveaux dérivés du s-acyl glutathion, leur synthèse et leur utilisation dans le traitement de maladies liées au stress oxydatif
US9974767B2 (en) Statins in the treatment of muscular dystrophies and myopathies
Parsons et al. MRZ-99030–A novel modulator of Aβ aggregation: I–mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD)
JP6595345B2 (ja) コンフォメーション病におけるβタンパク質凝集の新規の分子モジュレーターとしての化学シャペロニン
EP2403859A2 (fr) Pince moléculaire pour le traitement d'amyloses
CA3154596A1 (fr) Compositions solides comprenant un inhibiteur de pcsk9 et un sel d'acide n-(8-(2-hydroxybenzoyl)amino) caprylique
JP2019503356A (ja) エンドソーマルｇタンパク質共役受容体のトリパータイト・モジュレーター
JP2023057082A (ja) ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
EP1931394A2 (fr) Inhibiteurs de l'interaction du domaine apoe4 et methodes d'utilisation
CN116867488A (zh) 用于治疗干性老年性黄斑变性（amd）的组合物
JP6314135B2 (ja) ｉｎ−ｖｉｖｏで神経変性疾患（特にアルツハイマー病）に活性なリポソーム
JP6688503B2 (ja) 医薬用組成物
US20190192524A1 (en) Modulators of Caspase-6
CA3144618A1 (fr) Compositions solides comprenant un derive d'egf(a) et un sel d'acide n-(8-(2-hydroxybenzoyl) amino)caprylique
US20080227806A1 (en) Novel Drugs for Dementia
KR20210093900A (ko) 젬카빈, 이의 약학적으로 허용가능한 염, 이의 조성물 및 이의 사용 방법
Imbimbo et al. Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer’s disease
HUE034353T2 (en) Preparation containing a benzothiazolone compound
WO2017222042A1 (fr) Composition pharmaceutique ophtalmique
JP2001502897A (ja) 細胞毒性ペプチド
WO2024004231A1 (fr) INHIBITEUR DE γ-SÉCRÉTASE, INHIBITEUR DE PRODUCTION DE PEPTIDE Aβ ET PRODUIT PHARMACEUTIQUE
IL295452A (en) Use of cyclosporine analogs to treat leprosy
US20220305006A1 (en) Compositions and methods for the treatment of neurological diseases and disorders

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20200214